Chyntia Olivia Maurine Jasirwan

Dr. Chyntia Olivia Maurine Jasirwan

Rumah Sakit Umum Pusat Nasional Dr. Cipto Mangunkusumo, Jakarta, Indonesia
+1
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Bioscience of Microbiota, Food and Health
Verified
Journal Article
Open access
PDF file
CJChyntia Olivia Maurine Jasirwan
Chyntia Olivia Maurine Jasirwan
AMAkhmadu Muradi
Akhmadu Muradi
IHIrsan Hasan
Irsan Hasan
MSMarcellus Simadibrata
Marcellus Simadibrata
IRIkhwan Rinaldi
Ikhwan Rinaldi
We investigated the gut microbiota in patients with non-alcoholic fatty liver disease (NAFLD) and its correlation with fibrosis and steatosis stratified by body mass index, as reflected in the controlled attenuation parameter and transient elastography values. A cross-sectional study was performed on 37 patients with NAFLD at Cipto Mangunkusumo National General Hospital from December 2018 to March 2019. The gut microbiota was investigated in fecal samples with 16S RNA sequencing using the MiSeq next-generation sequencing platform (Illumina). NAFLD was more common in patients with metabolic syndrome. Firmicutes, Bacteroidetes, and Proteobacteria were the predominant phyla. Bacteroides was more dominant than Prevotella, contrary to the results of previous studies on healthy populations in Indonesia. Microbiota dysbiosis was observed in most samples. The gastrointestinal microbiota diversity was significantly decreased in patients with NAFLD, high triglyceride levels, and central obesity. The Firmicutes/Bacteroidetes ratio correlated with steatosis and obesity, whereas some of the other species in lower taxonomy levels were mostly associated with steatosis and obesity without fibrosis. Proteobacteria was the only phylum strongly correlated with fibrosis in patients with an average body mass index. The gut microbiota diversity was decreased in patients with NAFLD, high triglyceride levels, and central obesity, and certain gut microbes were correlated with fibrosis and steatosis.

1 January 2019 in Bioscience of Microbiota, Food and Health
Verified
Journal Article
Open access
PDF file
CJChyntia Olivia Maurine Jasirwan
Chyntia Olivia Maurine Jasirwan
CLCosmas Rinaldi Adithya Lesmana
Cosmas Rinaldi Adithya Lesmana
IHIrsan Hasan
Irsan Hasan
ASAndri Sanityosos Sulaiman
Andri Sanityosos Sulaiman
RGRino Alvani Gani
Rino Alvani Gani
Nonalcoholic fatty liver disease (NAFLD) is a hepatic manifestation of metabolic syndrome. Its prevalence increases with increasing rates of obesity, insulin resistance, and diabetes mellitus. The pathogenesis of NAFLD involves many factors, including the gastrointestinal microbiota. However, there is still debate about the impact of gut dysbiosis in the NAFLD disease progression. Therefore, this paper aims to review the relationship between gut microbiota and other risk factors for NAFLD and how gut dysbiosis plays a role in the pathogenesis of NAFLD. Hopefully, this paper can make an appropriate contribution to the development of NAFLD research in the future.

9 July 2020 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
CJChyntia Olivia Maurine Jasirwan
Chyntia Olivia Maurine Jasirwan
AFAlessa Fahira
Alessa Fahira
LSLianda Siregar
Lianda Siregar
ILImelda Loho
Imelda Loho
Background and aims: Hepatocellular carcinoma (HCC), the most common type of liver cancer, is one of the leading causes of cancer-related death worldwide with an inferior prognosis. In Indonesia, the average life expectancy is less than 5 months, with most patients being in an advanced stage wherein the survival rate is very low. Early detection through surveillance program is very crucial. HCC guidelines worldwide have provided surveillance recommendation through the examination of α-fetoprotein (AFP) and ultrasound for patients at risk in developing HCC. However, there have been some controversies regarding the usage of AFP concerning its low sensitivity and specificity in detecting HCC. Therefore, the effectiveness of AFP in the surveillance of HCC patients and identifying the parameters most associated with the increase of AFP ≥ 10 ng/ml in Indonesia should be evaluated. Methods: We analyzed medical records of HCC patients and those at high risk of developing HCC through cross-sectional study, including patients with cirrhosis and hepatitis B and C, from 2015 to 2017 who underwent treatment at the Cipto Mangunkusumo National General Hospital and Dharmais National Cancer Hospital, Indonesia. Results: The sensitivity and specificity of AFP in the surveillance of HCC in Indonesia with a cut-off of 10 ng/ml were 82.6 and 71.2%, respectively. The parameters most associated with the increase of AFP ≥10 ng/ml according to multivariate analysis were the etiology of hepatitis B, the stage of Barcelona Clinic Liver Cancer (BCLC) B and C, and the presence of cirrhosis, respectively. Conclusion: AFP can still be used in the surveillance of HCC in Indonesia for its high sensitivity value.

14 January 2014 in Microbiology and Immunology
Verified
Journal Article
Closed access
PDF file
CJChyntia Olivia Maurine Jasirwan
Chyntia Olivia Maurine Jasirwan
YFYoshikazu Furusawa
Yoshikazu Furusawa
HTHuamin Tang
Huamin Tang
TMTakahiro Maeki
Takahiro Maeki
YMYasuko Mori
Yasuko Mori

20 March 2019 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
YFYoga Fitriakusumah
Yoga Fitriakusumah
CLCosmas Rinaldi Adithya Lesmana
Cosmas Rinaldi Adithya Lesmana
WBWinda Permata Bastian
Winda Permata Bastian
CJChyntia Olivia Maurine Jasirwan
Chyntia Olivia Maurine Jasirwan
IHIrsan Hasan
Irsan Hasan
RGRino A. Gani
Rino A. Gani
Non-alcoholic fatty liver disease (NAFLD) is an emerging disease, where it can progress to non-alcoholic steatohepatitis (NASH) and lead to liver cirrhosis or liver cancer. Small intestinal bacterial overgrowth (SIBO) has been hypothesized to play an important role in NAFLD development and progression, however, there is still conflicting data about this phenomenon. Transient Elastography (TE) examination using controlled attenuation parameter (CAP) has been validated for liver disease progression assessment in NAFLD. It is non-invasive method and easy to perform in clinical practice. Therefore, we would like to know the role of SIBO in NAFLD and its possible impact on disease progression. A cross-sectional design study performed at outpatient’s Hepatobiliary clinic at tertiary referral university hospital in Jakarta. All recruited study subjects based on inclusions criteria underwent laboratory examination, transabdominal ultrasound examination, CAP-TE 502 (by Echosens, France), and glucose hydrogen breath test (GHBT) using portable hydrogen breath test apparatus (Gastro+™ Gastrolyzer by Bedfont Scientific Ltd). Stool sample examination was performed using RT-PCR. This study recruited 160 subjects with median age of 58 (22–78) years and 108 (67.5%) of them are female. SIBO (65,5%), DM (70.8%), dyslipidemia (75.2%), obesity (76.6%), and metabolic syndrome (73%) were more prevalent in NAFLD than non-NAFLD population. Bivariate analysis showed no significant association between SIBO and NAFLD development (p = 0.191; PR 0.871; CI 95% [0.306–1.269]). SIBO was also not associated with significant hepatic steatosis (p = 0.951; PR = 0.951; CI 95% [0.452–2.239]) and fibrosis (p = 0.371; PR = 1.369; CI 95% [0.608–3.772]). However, the presence of central obesity has significantly associated with the presence of SIBO (p = 0.001; PR = 0.378; CI 95% [0.021–0.478]). Based on stool sample analysis from 60 NAFLD patients, there is a significant correlation using Spearmen test between the presence of Bacteroides and the stage of fibrosis (p .037). Further analysis between obese NAFLD patients and non-obese NAFLD patients showing that there is a significant decrease of Bifidobacteria (p .047) and Lactobacillus (p .038) in obese NAFLD patients and a tendency of increase Bacteroides in obese NAFLD patients (p .572). SIBO is not associated with NAFLD development and progression.

1 February 2020 in Current Problems in Cancer
Verified
Journal Article
Closed access
CJChyntia Olivia Maurine Jasirwan
Chyntia Olivia Maurine Jasirwan
IHIrsan Hasan
Irsan Hasan
ASAndri Sanityoso Sulaiman
Andri Sanityoso Sulaiman
CLCosmas Rinaldi A. Lesmana
Cosmas Rinaldi A. Lesmana
JKJuferdy Kurniawan
Juferdy Kurniawan
RGRino Alvani Gani
Rino Alvani Gani